Pfizer (NYSE:PFE) has announced the launch of the Phase 2/3 EPIC-PEP study to test its oral antiviral candidate PF-07321332 as a post-exposure prophylaxis against COVID-19.
The EPIC-PEP study, whose name is an acronym of “Evaluation of Protease Inhibition for COVID-19 in Post-Exposure Prophylaxis,” will test the efficacy of PF-07321332 with low-dose ritonavir to prevent COVID-19 infection.
PF-07321332 and ritonavir are both protease inhibitors. AbbVie’s Ritonavir (Norvir) initially won FDA approval as an HIV treatment in 1996.
Trial participants must be 18 or older and live in the same household as an individual with laboratory-confirmed symptomatic SARS-CoV-2 infection.
The study will enroll up to 2,660 participants.
“Given the continued emergence and evolution of SARS-CoV-2 variants and their immense impact, we continue to work diligently to develop and study new ways that our investigational oral antiviral candidate could potentially lower the impact of COVID-19, not only on patients’ lives but also the lives of their families and household members,” said Dr. Mikael Dolsten, chief scientific officer and president, worldwide R&D and Medical at Pfizer.
Pfizer has several clinical trials under the EPIC umbrella, including those testing the drug’s efficacy in patients with a high risk of developing severe COVID-19.
Filed Under: clinical trials, Drug Discovery, Infectious Disease